The growth of Viagra and its influence on the pharmaceutical landscape presents a intricate question for shareholders. While the initial sales statistics were remarkable, the intellectual property has expired, leading to a deluge of generic alternatives that are chipping away at earnings. Moreover, the sector is facing difficulties related to demog